Call Us!

+1 310-279-5152
+1 800-859-7036

 Call 1-800-859-7036 anytime to order or
discuss your options with our oncologists.

Scientific Research:

Clinical Trials

Summary of Clinical Trials

The following information is a summation of an eight-year third stage clinical trial sponsored by the Cuban company, Labiofirm. In this study, 8,302 patients representing a wide spectrum of cancer types and severities were treated with blue scorpion serum.

The study did not begin with 8,302 patients, but expanded to include 8,302 patients over this eight-year period.

A variety of cancers were studied with breast, brain, lung, prostate, and colon cancers being the most common studied. Cancers of the larynx, lung, and uterus showed the greatest benefit over the course of the study.

Introduction

In 1985, a group of researchers from the Medical Sciences Department in Guantanamo began a research project designed to show the anti-tumoral effect of the Rhopalurus junceus(blue) scorpion’s serum.

A strategy for investigating this serum was established.

Materials and Methods

To conduct their research, Labiofirm used summaries of the clinical history of each patient issued by the doctor who tracks the patient through different medical institutions.

Labiofirm evaluated each patient monthly. During their evaluation, they spoke with the patient or a close family member and organized our records according to the type of neoplasia.

Table 1. Distribution by age groups.

Age groups	Quantity of patients	Women	Men	Percent
0 - 20	421	227	194	5.05
21 - 40	1333	1012	321	16.1
41 - 60	3531	2481	1050	41.5
61 - 80	2974	1464	1460	35.2
81 - 100	93	35	58	1.7
Total	8302	5219	3083

 

Table 2. Less frequent tumors

Type of tumor	Number of patients	Percent
Tumor of the Larynx	176	2.11i
Tumors  of the bladder-urethra	156	1.87h
Tumor of the liver, gallbladder and biliary tract	84	1.01i
Gastroesophageal tumours	78	0.93i
Skin tumors	72	0.86hi
Mouth and nasal-pharynx tumor	68	0.81hi
Tumor of the pancreas	56	0.67i

 

Table 3: Time Taking Blue Scorpion Serum

Time in year	Quantity of patients	Percent
8 or more	187	2.25
7	246	2.96
6	353	4.25
5	512	6.16
4	705	8.49
3	814	9.80
2	1000	12.04
1	2502	30.13
(6 - 11) months	1983	23.88
Total	8302	100.00

It is important to remember that Labiofirm’s did not organize their study as an American or European study is normally organized. It did not begin with 8,302 patients, but a total of 8,302 patients were studied over eight years. Of these 8,302 patients, 66.05% of them took blue scorpion venom for two years or less. This 66.05% includes four groups: 1) Those that went into remission and no longer felt they needed to take the serum. 2) Those that joined the study late in the last two years and were still taking the serum at the conclusion of the study. 3) Those that died. 4) Those that left the study on their own for unspecified reasons. Labiofirm has not made available the size of each of these four groups. Therefore, there is some difficulty in assessing the detail of the final data. However, the positive nature of the final conclusion is clear. Medolife has applied for FDA clinical trials to produce better clarified data on the subject.

An Analysis of the Efficacy of Blue Scorpion Serum for Three Specific Cancers

The following section was composed by Labiofirm which assesses the effectiveness of blue scorpion serum for specific cancers.

• Table 4 describes how long people were taking blue scorpion serum as a part of the study for these three cancers.
• Table 5 describes the state of health for patients with laryngeal cancer at the end of the study.
• Table 6 describes the state of health for patients with lung cancer at the end of the study.
• Table 7 describes the state of health for patients with uterine cancer at the end of the study.

Tables 5, 6, and 7 use the ECOG scale and the Karnofsky scale to describe the health and activity of the patients. These scales are explained after Table 7.

Table 4: Length of Blue Scorpion Serum Use

Sickness/time in years	Lung tumor	Uterine tumor	Larynx tumor	Total
8	14	17	6	37
7	17	19	11	47
6	19	11	12	42
5	27	22	15	64
4	31	39	18	88
3	37	59	16	112
2	58	78	30	166
1	316	91	36	443
(6 - 11) months	218	86	32	336
Total	737	422	176	1335

 

Table 5: Scale of Tumors of the Larynx

ECOG Scale	Total	%	Karnofsky Scale	Total	%
0	74	42	100	0	_
			90	74	42
1	65	36.9	80	34	19.3
			70	31	17.6
2	31	17.6	60	19	10.7
			50	12	6.8
3	0	_	40	_	_
			30	_	_
4	0	_	20	_	_
			10	_	_
5	6	3.40	0	6	3.40

 

Table 6: Scale of Lung Tumors

ECOG Scale	Total	%	Karnofsky Scale	Total	%
0	85	11.52	100	14	1.89
			90	71	9.63
1	258	35.00	80	132	17.91
			70	126	17.09
2	187	25.36	60	115	15.60
			50	72	9.76
3	78	10.57	40	43	5.83
			30	35	4.74
4	43	5.82	20	14	1.89
			10	29	3.93
5	86	11.66	0	86	11.66

 

Table 7: Scale of Tumors of the Uterus

ECOG Scale	Total	%	Karnofsky Scale	Total	%
0	36	8.53	100	5	1.18
			90	31	7.34
1	155	36.72	80	81	19.19
			70	74	17.53
2	98	23.22	60	56	13.27
			50	42	9.95
3	46	10.90	40	24	5.68
			30	22	5.21
4	62	14.69	20	38	9.0
			10	24	5.68
5	25	5.92	0	25	5.92

 

Evaluation of the clinical state

ECOG Scale		Karnofsky Scale
Grade	Description	Percent	Description
0	Capable of carrying out a normal physical activity without restrictions.	100	Normal, no symptoms or evidence of illness.
		90	Normal activity, slight symptoms or signs of illness.
1	Symptomatic, but not hospitalized. Restriction on vigorous physical activities, but an outpatient and able to undertake light chores or those of a sedentary nature.	80	Normal activity with effort. Some symptoms or indications of illness.
		70	Able to care for self, unable to undertake normal activity or active work.
2	In bed less than 50% of the time, not hospitalized, able to care for self, but unable to work more than 50% of the time when out of bed.	60	Needs occasional assistance, but able to attend to the greater part of his or her personal necessities.
		50	Requires assistance and frequent medical attention.
3	Capable of personal care, but confined to a bed or chair more than 50% of the time.	40	Bedridden, requiring assistance and special care.
		30	Severely incapacitated. Condition is dire and death is imminent. Requires hospitalized.
4	Completely incapable of any effort, totally confined to bed.	20	A grave stale. Intensive support. Requires hospitalized.
		10	Very grave state (moribund). Fatal process progresses rapidly.
5	Death	0	Death

 

Medolife Summary

The above statistics do not include information regarding which stage of cancer which the patient was in at the beginning of their treatment. However, it should be noted that a significant percentage were in stage four cancer when they initially joined the study.

In addition, of the three sample cancers that were focused upon in the report (larynx, lung, and uterine), 64.6% of the patients in this study achieved a 60 to 100 score on the Karnofsky Scale. This means 64.6% were able to maintain a relatively normal to completely normal life after taking blue scorpion serum for as little as six months.

Quality of Life for Sample Cancers

Cancer of the Larynx

Cancer of the Lungs

Cancer of the Uterus

Survival Rates

For the three cancers featured in this report (larynx, lung, and uterine) the collective survival rate was 91.24% for the patients in the clinical trial.